Eupraxia Pharmaceuticals (EPRX) said Thursday that it has reached its target enrollment of 120 patients for a phase 2b study of EP-104GI in eosinophilic esophagitis.
The company said it has treated its 120th patient in the placebo-controlled trial, which is evaluating doses of 120mg and 160mg of EP-104GI. Interim results are expected in December, Eupraxia said.
Eosinophilic esophagitis is an inflammatory-mediated disease, which creates pain and difficulty for patients when swallowing food.
Shares of Eupraxia were down 4.4% pre-bell Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments